Also Known As
脑钠肽
前脑钠肽
正式名称
B-型脑钠肽; N-末端前b-型脑钠肽
本文最后审核 时间
本文 最后修改 时间
2018/01/19.

 

快速浏览
为何检测?

有助于诊断心力衰竭及评估其严重性。

何时检测?

当有心力衰竭的症状,如呼吸急促、疲劳或者正在接受心力衰竭治疗时。

何种样本?

采自肘静脉的血液样本。

是否需要作试验前准备?

不需要。

检测什么?

这些检查可检测血中脑利钠肽(BNP)或前脑钠肽(NT-proBNP)的浓度。正常情况下,心脏可产生少量的前体蛋白pro-BNP,经过裂解可释放活性激素BNP和一个无活性片段NT-proBNP。BNP有助于调节血容量,帮助心脏将血液泵到全身。BNP和NT-proBNP主要由左心室(主要的泵血腔)产生,当左心室松弛,不得不更用力的泵血时,血中的BNP和NT-proBNP便显著增加。这种情况可发生在心力衰竭以及影响心脏和血液循环系统的其他疾病中。

测试样本如何采集?

自肘静脉采集血液样本。

是否需要进行任何试验前准备以保证样本的质量?

不需要任何试验前准备。

Accordion Title
常见问题
  • 有何用途?

    不论是BNP 还是 NT-proBNP都可用于诊断心力衰竭和对心竭的严重程度分级。有很多原因可引起心力衰竭。目前,主要通过症状诊断该病,如腿浮肿(水肿)、呼吸困难、呼吸急促、疲劳以及胸部X射线和称为超声心动图的超声波检查。然而,心力衰竭仍常常难以与其他疾病进行鉴别。BNP 和NT-proBNP水平则有助于医生区分心力衰竭和其他疾病,如肺部疾病。准确诊断至关重要,因为心力衰竭可通过多种治疗方式控制。

  • 何时检测?

    以下情况下需要做BNP或NT-proBNP检查:

    • 在医生办公室,如出现心力衰竭症状。
    • 在急诊室,如果患者生命垂危,医生需要尽快明确您是否突发心力衰竭或其他问题。
    • 监测心力衰竭治疗效果。
  • 试验结果的含义?

    高于正常结果表明出现心力衰竭,血液中BNP 或NT-proBNP的水平与心力衰竭的严重性正相关。高水平BNP 或NT-proBNP与病程结果(预后)不佳有关。

  • 还有什么我需要了解的吗?

    大多数患者在接受药物如ACE抑制剂,β -受体阻滞剂和利尿剂的治疗后,其BNP或NT-proBNP水平下降。BNP 和NT-proBNP水平往往随着年龄的增大而增加。肾脏疾病患者的NT-proBNP和BNP也可升高。

            虽然左心室功能障碍时BNP 或NT-proBNP增加,且两者都可以检测,但它们之间是不能替换的,且结果并不能直接比较。

  • 心力衰竭有有多常见?

            有500万美国人患有该病,每年有55万新的病例被确诊。

  • 如何治疗心力衰竭?

            有关治疗信息,请访问美国心脏协会的网站。

参考文献

Sources Used in Current Review

Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE, eds. St. Louis: Elsevier Saunders; 2006 pp. 1630-1631.

Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry. AACC Press, Washington, DC; p. 264.

deFilippi C. Natriuretic Peptides for Diagnosing Heart Failure and Beyond: What We Know in 2007. (May 24, 2007) Medscape Today. Available online at http://www.medscape.com/viewarticle/557030 through http://www.medscape.com. Accessed September 2008.

Maher KO et al. B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children. Pediatrics 2008 Jun; 121:e1484. Available online at http://pediatrics.aappublications.org/cgi/content/full/121/6/e1484?linkType=FULL&journalCode=pediatrics&resid=121/6/e1484 through http://pediatrics.aappublications.org. Accessed September 2008.

Sources Used in Previous Reviews

Interview with Alan H.B. Wu, PhD. Director, Clinical Chemistry, Hartford Hospital, Hartford, CT.

"First Blood Test for Congestive Heart Failure Wins FDA Clearance." Clinical Laboratory Strategies, December 2000, Vol. 5, No. 12, p.1.

Thomas, Clayton L., Editor (1997). Taber’s Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby’s Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Tang, W. (2004 February 27). NACB: Recommendations for the use of Cardiac Biomarkers in Heart Failure. NACB: Recommendations for the use of Cardiac Biomarkers in Heart Failure – Chapter 2 [Draft Guidelines]. Available online at http://www.nacb.org/lmpg/biomark/card_biomarkers_chp2.doc through http://www.nacb.org.

Bay, M. et. al. (2003). NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart ONLINE Heart 2003;89:150-154 [On-line journal]. Available online at http://heart.bmjjournals.com/cgi/content/full/89/2/150 through http://heart.bmjjournals.com.

Diagnostic Products Corporation Acquires Nonexclusive Rights to a Key Cardiac Marker, NT-proBNP, from Roche Diagnostics—Agreement widens access to unique marker for heart failure and allows for better/earlier/improved therapy. (2004 February 11) DPC [On-line press release]. Available online at http://www.dpcweb.com/newsreleases/2004/february/ntprobnp.htm through http://www.dpcweb.com.

Roche Receives FDA Clearance for Elecsys proBNP Assay – First Automated Blood Test to Aid in the Diagnosis of Congestive Heart Failure (2002). Roche Diagnostics [On-line press release]. Available online at http://www.roche-diagnostics.com/press_lounge/press_releases/archive/2002_11_20.html through http://www.roche-diagnostics.com